

COVID-19 Vaccine Update

Caterina Liu, MD MPH
CDPH Immunization Branch

Moderna Announces COVID-19 Vaccine Adolescent Trial Results

- Moderna announced Phase III clinical trial results in adolescents 12-17 on 5/25/21
- Vaccine efficacy 100% after 2 doses against symptomatic COVID-19
- Safety and tolerability profile consistent with the Phase III adult trials
- Moderna plans to submit data to FDA in June.
- [Press release](#)

Myocarditis/Pericarditis potentially associated with mRNA COVID-19 vaccine

- CDC is closely following reports of myocarditis or pericarditis following COVID-19 vaccination.
- Investigation of these reports is in progress to determine whether or not COVID-19 vaccines are a contributing factor.
- Evaluating providers should report cases of myocarditis/ pericarditis after vaccination promptly to the Vaccine Adverse Events Reporting System (VAERS): <https://vaers.hhs.gov/reportevent.html>

Myocarditis/Pericarditis potentially associated with mRNA COVID-19 vaccine

Vaccine Safety Technical (VaST) Work Group reviewed updates from several national vaccine safety surveillance systems (DoD, VAERS, VSD, VA, CISA):
<https://www.cdc.gov/vaccines/acip/work-groups-vast/technical-report-2021-05-17.html>

- Few reports of myocarditis to date following receipt of mRNA vaccines
- Most cases appear to be mild and of brief duration
- Follow-up of cases is ongoing
- Cases seem to occur:
 - predominantly in adolescents and young adults.
 - more often in males than females.
 - more often following dose 2 than dose 1.
 - typically, within 4 days after vaccination.

FDA Safety Communication – 5/19/21

- Do not use currently authorized SARS-CoV-2 antibody tests to evaluate a person's level of immunity or protection from COVID-19, **either from vaccination or prior disease**
- While a positive antibody test can indicate an immune response has occurred (seroconversion), and failure to detect such a response may suggest a lack of immune response, more research is needed
- Concern that results may be interpreted as an indication of a specific level of immunity or protection from SARS-CoV-2 infection and, consequently, people may take fewer precautions against SARS-CoV-2 exposure
- [Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication | FDA](#)